{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03921021: Phase 2 Interventional Completed Esophagogastric Adenocarcinoma
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04614948: Phase 3 Interventional Completed Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01436968: Phase 3 Interventional Active, not recruiting Prostate Cancer
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04400838: Phase 2/Phase 3 Interventional Active, not recruiting Coronavirus
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02028442: Phase 1/Phase 2 Interventional Completed Solid Tumours of Epithelial Origin
(2012)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03398655: Phase 3 Interventional Completed Recurrent Platinum Resistant Ovarian Cancer
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03780049: Phase 3 Interventional Unknown status Hepatocellular Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03563144: Phase 2 Interventional Withdrawn Metastatic Pancreatic Cancer
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03554109: Phase 2 Interventional Withdrawn Triple Negative Breast Cancer (TNBC)
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00006106: Phase 1 Interventional Withdrawn Lip and Oral Cavity Cancer
(1999)
Source URL:
Class:
STRUCTURALLY DIVERSE